Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer

References

• Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683–694. 10.1056/NEJMoa2106391. .
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–366.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865–875.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. 10.1056/NEJMoa1510665. .
   PubMed Web of Science ®Google Scholar
• Massari F, Nunno VD, Mollica V, et al. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy. 2019;11(17):1507–1521. DOI:10.2217/imt-2019-0115
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. 10.1056/NEJMoa1712126. .
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. 10.1056/NEJMoa2026982. .
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. 10.1056/NEJMoa1816714. .
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. 10.1056/NEJMoa2035716. .
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. 10.1056/NEJMoa1816047. .
   PubMed Web of Science ®Google Scholar
• Huang JJ, Hsieh JJ. The therapeutic landscape of renal cell carcinoma: from the dark age to the golden age. Semin Nephrol. 2020;40(1):28–41.
   PubMed Web of Science ®Google Scholar
• Allaf M, Kim SE, Harshman LC, et al. LBA67 - phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a national clinical trials network trial. Ann Oncol. 2022;33(suppl_7):S808–869. DOI:10.1016/j.annonc.2022.08.072
   Google Scholar
• Motzer RJ, Russo P, Gruenwald V, et al. LBA4 - adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: results from the randomized, phase III CheckMate 914 trial. Ann Oncol. 2022;33(suppl_7):S808–869. DOI:10.1016/j.annonc.2022.08.069
   Web of Science ®Google Scholar
• Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022;400(10358):1103–1116. [published online ahead of print, 2022 Sep 9] S0140-6 736(22)01658-0.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Rosellini M, Mollica V, et al. The molecular characteristics of non-clear cell renal cell carcinoma: what’s the story morning glory? Int J Mol Sci. 2021;22(12):6237. DOI:10.3390/ijms22126237
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18(16):2972–2980. DOI:10.1200/JCO.2000.18.16.2972
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124. DOI:10.1056/NEJMoa065044
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590. DOI:10.1200/JCO.2008.20.1293
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–731. DOI:10.1056/NEJMoa1303989
   PubMed Web of Science ®Google Scholar
• Zarkar A, Pirrie S, Stubbs C, et al. A study of pazopanib safety and efficacy in patients with advanced clear cell renal cell carcinoma and ecog performance status 2 (pazo2): an open label, multicentre, single arm, phase ii trial. Clin Genitourin Cancer. 2022;20(5):473–481. [published online ahead of print, 2022 Jun 14] S1558-7673(22)00136-7.
   PubMedGoogle Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance a031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591–597. [published correction appears in J Clin Oncol. 2017 Nov 10;35(32):3736] [published correction appears in J Clin Oncol. 2018 Feb 10;36(5):521].
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94(94):115–125. [published correction appears in Eur J Cancer. 2018 Nov;103:287].
   PubMedGoogle Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134. DOI:10.1056/NEJMoa060655
   PubMed Web of Science ®Google Scholar
• Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol. 2012;30(14):1678–1685. DOI:10.1200/JCO.2011.35.3524
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791–3799. DOI:10.1200/JCO.2012.47.4940
   PubMed Web of Science ®Google Scholar
• Rizzo A, Rosellini M, Marchetti A, et al. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy. 2021;13(8):685–692. DOI:10.2217/imt-2020-0323
   PubMed Web of Science ®Google Scholar
• Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. DOI:10.1136/esmoopen-2020-001079
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888–898. DOI:10.1016/S1470-2045(22)00290-X
   PubMed Web of Science ®Google Scholar
• Powles T, Plimack ER, Soulieres D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomized, open-label, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1563–1573.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030–1039. DOI:10.1016/j.annonc.2020.04.010
   PubMed Web of Science ®Google Scholar
• Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–2415. 10.1016/S0140-6736(19)30723-8. .
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Powles T, Atkins MB, et al. Final overall survival and molecular analysis in immotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 2022;8(2):275–280. DOI:10.1001/jamaoncol.2021.5981
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–1939. [published correction appears in Lancet. 2012 Nov 24;380(9856):1818].
   PubMed Web of Science ®Google Scholar
• Ornstein MC, Pal SK, Wood LS, et al. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2019;20(10):1386–1394. DOI:10.1016/S1470-2045(19)30513-3
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–1823. 10.1056/NEJMoa1510016. .
   PubMed Web of Science ®Google Scholar
• Powles T, Motzer RJ, Escudier B, et al. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer. 2018;119(6):663–669. DOI:10.1038/s41416-018-0164-0
   PubMed Web of Science ®Google Scholar
• Procopio G, Pircher C, Claps M, et al. A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: the BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36). J Clin Oncol. 2021;39(6(suppl)):326. DOI:10.1200/JCO.2021.39.6_suppl.326
   Web of Science ®Google Scholar
• Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21(1):95–104. DOI:10.1016/S1470-2045(19)30735-1
   PubMed Web of Science ®Google Scholar
• Tannir NM, Agarwal N, Porta C, et al. CANTATA: primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies. J Clin Oncol. 2021;39(15_suppl):4501.
   Google Scholar
• McKay RR, McGregor BA, Xie W, et al. Optimized management of nivolumab and ipilimumab in advanced renal cell carcinoma: a response-based phase II study (OMNIVORE). J Clin Oncol. 2020;38(36):4240–4248. DOI:10.1200/JCO.20.02295
   PubMed Web of Science ®Google Scholar
• Grande E, Alonso-Gordoa T, Reig O, et al. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy. ESMO Open. 2022;7(2):100463. DOI:10.1016/j.esmoop.2022.100463
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Kluger HM, George S, et al. FRACTION-RCC: innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020;38(15_suppl):5007. DOI:10.1200/JCO.2020.38.15_suppl.5007
   Web of Science ®Google Scholar
• Atkins MB, Jegede OA, Haas NB, et al. Study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 2022;40(25):2913–2923. [published online ahead of print, 2022 Apr 20].
   PubMed Web of Science ®Google Scholar
• Albiges L, Schmidinger M, Taguieva-Pioger N, et al. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future Oncol. 2022;18(8):915–926. DOI:10.2217/fon-2021-1006
   PubMed Web of Science ®Google Scholar
• Mennitto A, Zattarin E, Di Maio M, et al. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). Expert Rev Anticancer Ther. 2022;22(1):115–121. DOI:10.1080/14737140.2022.2002688
   PubMed Web of Science ®Google Scholar
• Santoni M, Massari F, Bracarda S, et al. Cabozantinib in patients with advanced renal cell carcinoma primary refractory to first-line immunocombinations or tyrosine kinase inhibitors. Eur Urol Focus. 2022;8(6):1696–1702. [published online ahead of print, 2022 Feb 19] S2405-4569(22)00049-9.
   PubMedGoogle Scholar
• Powles TB, Oudard S, Grünwald V, et al. 718P a phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment. Ann Oncol. 2020;31:S564.
   Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482. [published correction appears in Lancet Oncol. 2016 Jul;17 (7):e270] [published correction appears in Lancet Oncol. 2018 Oct;19(10):e509].
   PubMed Web of Science ®Google Scholar
• Pal SK, Puente J, Heng DYC, et al. Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). J Clin Oncol. 2021;39(6_suppl):307. DOI:10.1200/JCO.2021.39.6_suppl.307
   Web of Science ®Google Scholar
• Albiges L, Barthélémy P, Gross-Goupil M, et al. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2021;32(1):97–102.
   PubMed Web of Science ®Google Scholar
• Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385(22):2036–2046. DOI:10.1056/NEJMoa2103425
   PubMed Web of Science ®Google Scholar
• Bauer TM, Choueiri TK, Papadopoulos KP, et al. The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): updated follow-up of a phase I/II study. J Clin Oncol. 2021;39(6_suppl):273. DOI:10.1200/JCO.2021.39.6_suppl.273
   PubMedGoogle Scholar
• Choueiri TK, Bauer TM, McDermott DF, et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(6_suppl):272. DOI:10.1200/JCO.2021.39.6_suppl.272
   Web of Science ®Google Scholar
• Huo JL, Wang YT, Fu WJ, et al. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022;13:956090.
   PubMed Web of Science ®Google Scholar
• Grimm M-O, Esteban E, Barthelemy P, et al. Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC). J Clin Oncol. 2021;39(15_suppl):4576. DOI:10.1200/JCO.2021.39.15_suppl.4576
   Google Scholar
• Sepe P, Ottini A, Pircher CC, et al. Characteristics and treatment challenges of non-clear cell renal cell carcinoma. Cancers (Basel). 2021;13(15):3807. DOI:10.3390/cancers13153807
   PubMed Web of Science ®Google Scholar
• Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26(2):202–209. DOI:10.1007/s12032-009-9177-0
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–388. DOI:10.1016/S1470-2045(15)00515-X
   PubMed Web of Science ®Google Scholar
• Tannir NM, Jonasch E, Albiges L, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69(5):866–874. DOI:10.1016/j.eururo.2015.10.049
   PubMed Web of Science ®Google Scholar
• IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society, Ahrens M, Scheich S, et al. Non-clear cell renal cell carcinoma - pathology and treatment options. Oncol Res Treat. 2019;42(3):128–135.
   PubMedGoogle Scholar
• Knox JJ, Barrios CH, Kim TM, et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2018;29(11):2269. DOI:10.1093/annonc/mdx807
   PubMed Web of Science ®Google Scholar
• Escudier B, Molinie V, Bracarda S, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: rAPTOR final analysis. Eur J Cancer. 2016;69:226–235.
   PubMed Web of Science ®Google Scholar
• Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French genitourinary group (GETUG)†. Ann Oncol. 2015;26(6):1123–1128. DOI:10.1093/annonc/mdv149
   PubMed Web of Science ®Google Scholar
• Nandagopal L, Sonpavde GP, Agarwal N. Investigational MET inhibitors to treat renal cell carcinoma. Expert Opin Investig Drugs. 2019;28(10):851–860.
   PubMedGoogle Scholar
• Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–186. DOI:10.1200/JCO.2012.43.3383
   PubMed Web of Science ®Google Scholar
• Schöffski P, Wozniak A, Escudier B, et al. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur J Cancer. 2017;87:147–163.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Heng DYC, Lee JL, et al. Efficacy of Savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol. 2020;6(8):1247–1255. DOI:10.1001/jamaoncol.2020.2218
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Plimack E, Arkenau HT, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol. 2017;35(26):2993–3001. DOI:10.1200/JCO.2017.72.2967
   PubMed Web of Science ®Google Scholar
• Pal SK, Tangen C, Thompson IM Jr, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. DOI:10.1016/S0140-6736(21)00152-5
   PubMed Web of Science ®Google Scholar
• Hanif A, Pandey M, Khan S, et al. Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8(8):1606639. DOI:10.1080/2162402X.2019.1606639
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chittoria N, Choueiri TK, et al. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer. 2015;13(2):e79–85. DOI:10.1016/j.clgc.2014.08.011
   PubMed Web of Science ®Google Scholar
• Michaelson MD, McKay RR, Werner L, et al. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015;121(19):3435–3443. DOI:10.1002/cncr.29503
   PubMed Web of Science ®Google Scholar
• Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (groupe d’Etudes des tumeurs uro-génitales) study. J Urol. 2007;177(5):1698–1702. DOI:10.1016/j.juro.2007.01.063
   PubMed Web of Science ®Google Scholar
• Procopio G, Ratta R, Colecchia M, et al. A phase II study of cabozantinib as first-line treatment in metastatic collecting ducts carcinoma: the BONSAI trial. J Clin Oncol. 2019;37:578.
   Web of Science ®Google Scholar
• Zoumpourlis P, Genovese G, Tannir NM, et al. Systemic therapies for the management of non-clear cell renal cell carcinoma: what works, what doesn’t, and what the future holds. Clin Genitourin Cancer. 2021;19(2):103–116. DOI:10.1016/j.clgc.2020.11.005
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 2004;22(18):3720–3725. DOI:10.1200/JCO.2004.10.155
   PubMed Web of Science ®Google Scholar
• Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the juvenile RCC network. Ann Oncol. 2010;21(9):1834–1838. DOI:10.1093/annonc/mdq029
   PubMed Web of Science ®Google Scholar
• Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67(3):919–929. DOI:10.1158/0008-5472.CAN-06-2855
   PubMed Web of Science ®Google Scholar
• Graham J, Wells JC, Dudani S, et al. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. Eur J Cancer. 2022;171:124–132.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Lee JL, Ziobro M, et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021;39(9):1029–1039. 10.1200/JCO.20.02365.
   PubMed Web of Science ®Google Scholar
• Lee CH, Voss MH, Carlo MI, et al. Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol. 2022;40(21):2333–2341. DOI:10.1200/JCO.21.01944
   PubMed Web of Science ®Google Scholar
• Suarez Rodriguez C, Larkin J, Patel P, et al. Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer. J Clin Oncol. 2021;39(15_suppl):4511. DOI:10.1200/JCO.2021.39.15_suppl.4511
   Web of Science ®Google Scholar
• Pal SK, McGregor B, Suárez C, et al. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study. J Clin Oncol. 2021;39(33):3725–3736. DOI:10.1200/JCO.21.00939
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Eto M, Kopyltsov E, et al. 660P phase III CLEAR trial in advanced renal cell carcinoma (aRCC): outcomes in subgroups and toxicity update. Ann Oncol. 2021;32(suppl_5):S683–685. DOI:10.1016/j.annonc.2021.08.056
   Google Scholar
• Iacovelli R, Ciccarese C, Bria E, et al. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: a meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer. 2020;136:195–203.
   PubMed Web of Science ®Google Scholar
• Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2021;27(1):78–86. DOI:10.1158/1078-0432.CCR-20-2063
   PubMed Web of Science ®Google Scholar
• Rini BI, Plinick ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol. 2019;37(15_suppl):4500. 37:15s (suppl; abstr 4500).
   Web of Science ®Google Scholar
• Rini BI, Motzer RJ, Powles T, et al. Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: a prespecified subgroup analysis of the immotion151 clinical trial. Eur Urol. 2021;79(5):659–662. DOI:10.1016/j.eururo.2020.06.021
   PubMed Web of Science ®Google Scholar
• Sharma R, Kadife E, Myers M, et al. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. J Exp Clin Cancer Res. 2021;40(1):186. DOI:10.1186/s13046-021-01961-3
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799. DOI:10.1200/JCO.2008.21.4809
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–148. DOI:10.1016/S1470-2045(12)70559-4
   PubMed Web of Science ®Google Scholar
• Dudani S, Savard MF, Heng DYC. An update on predictive biomarkers in metastatic renal cell carcinoma. Eur Urol Focus. 2020;6(1):34–36.
   PubMedGoogle Scholar
• Ciccarese C, Iacovelli R, Porta C, et al. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. Cancer Treat Rev. 2021;100:102295.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Banchereau R, Hamidi H, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38(6):803–817.e4. 10.1016/j.ccell.2020.10.011. .
   PubMed Web of Science ®Google Scholar
• Iacovelli R, De Giorgi U, Galli L, et al. Is it possible to improve prognostic classification in patients affected by metastatic renal cell carcinoma with an intermediate or poor prognosis? Clin Genitourin Cancer. 2018;16(5):355–359.e1. DOI:10.1016/j.clgc.2018.04.007
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–3385. DOI:10.1158/0008-5472.CAN-05-4303
   PubMed Web of Science ®Google Scholar
• Ueda K, Suekane S, Kurose H, et al. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Urol Oncol. 2018;36(11):499.e9–499.e16. doi:10.1016/j.urolonc.2018.07.003.
   PubMedGoogle Scholar
• Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015;21(5):1071–1077. DOI:10.1158/1078-0432.CCR-14-1993
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Nolè F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol. 2016;11(2):143–148. DOI:10.1007/s11523-015-0392-7
   PubMed Web of Science ®Google Scholar
• Flaifel A, Xie W, Braun DA, et al. PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN. Clin Cancer Res. 2019;25(20):6080–6088. DOI:10.1158/1078-0432.CCR-19-1135
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370–1385. DOI:10.1016/S1470-2045(19)30413-9
   PubMed Web of Science ®Google Scholar
• Carretero-González A, Lora D, Martín Sobrino I, et al. The value of pd-l1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel). 2020;12(7):1945. DOI:10.3390/cancers12071945
   PubMed Web of Science ®Google Scholar
• Zhu J, Armstrong AJ, Friedlander TW, et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: pD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018;6(1):4. DOI:10.1186/s40425-018-0314-1
   PubMed Web of Science ®Google Scholar
• Callea M, Albiges L, Gupta M, et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res. 2015;3(10):1158–1164. DOI:10.1158/2326-6066.CIR-15-0043
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501.
   PubMed Web of Science ®Google Scholar
• Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. DOI:10.1038/nature12477
   PubMed Web of Science ®Google Scholar
• Zhang C, Li Z, Qi F, et al. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma. Ann Transl Med. 2019;7(22):648. DOI:10.21037/atm.2019.10.84
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206. DOI:10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Choueiri TK, McDermott DF, et al. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 2022;10(3):e004316. DOI:10.1136/jitc-2021-004316
   PubMed Web of Science ®Google Scholar
• McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–757. DOI:10.1038/s41591-018-0053-3
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Robbins PB, Powles T, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial. Nat Med. 2020;26(11):1733–1741. DOI:10.1038/s41591-020-1044-8
   PubMed Web of Science ®Google Scholar
• Schnidrig D, Turajlic S, Litchfield K. Tumour mutational burden: primary versus metastatic tissue creates systematic bias. Immunooncol Technol. 2019;4:8–14.
   PubMedGoogle Scholar
• Steindl A, Alpar D, Heller G, et al. Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases. ESMO Open. 2021;6(2):100057. DOI:10.1016/j.esmoop.2021.100057
   PubMed Web of Science ®Google Scholar
• Ciccarese C, Brunelli M, Montironi R, et al. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016;49:37–44.
   PubMed Web of Science ®Google Scholar
• Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002;94(20):1569–1575. DOI:10.1093/jnci/94.20.1569
   PubMedGoogle Scholar
• Smits KM, Schouten LJ, van Dijk BA, et al. Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res. 2008;14(3):782–787. DOI:10.1158/1078-0432.CCR-07-1753
   PubMed Web of Science ®Google Scholar
• Büscheck F, Fraune C, Simon R, et al. Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. Oncotarget. 2020;11(3):237–249. DOI:10.18632/oncotarget.27428
   PubMedGoogle Scholar
• Stenehjem DD, Hahn AW, Gill DM, et al. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS ONE. 2019;14(1):e0210415. DOI:10.1371/journal.pone.0210415
   PubMed Web of Science ®Google Scholar
• Joseph RW, Kapur P, Serie DJ, et al. Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J Urol. 2016;195(1):180–187. DOI:10.1016/j.juro.2015.07.113
   PubMed Web of Science ®Google Scholar
• Carril-Ajuria L, Santos M, Roldán-Romero JM, et al. Prognostic and predictive value of PBRM1 in clear cell renal cell carcinoma. Cancers (Basel). 2019;12(1):16.
   PubMed Web of Science ®Google Scholar
• Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359:801–806.
   PubMed Web of Science ®Google Scholar
• Braun DA, Ishii Y, Walsh AM, et al. Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma. JAMA Oncol. 2019;5(11):1631–1633. DOI:10.1001/jamaoncol.2019.3158
   PubMed Web of Science ®Google Scholar
• Ho TH, Choueiri TK, Wang K, et al. Correlation between molecular subclassifications of clear cell renal cell carcinoma and targeted therapy response. Eur Urol Focus. 2016;2(2):204–209. DOI:10.1016/j.euf.2015.11.007
   PubMedGoogle Scholar
• Hagiwara M, Fushimi A, Matsumoto K, et al. The significance of PARP1 as a biomarker for predicting the response to PD-L1 blockade in patients with PBRM1-mutated clear cell renal cell carcinoma. Eur Urol. 2022;81(2):145–148. DOI:10.1016/j.eururo.2021.09.024
   PubMedGoogle Scholar
• Di Nunno V, Frega G, Santoni M, et al. BAP1 in solid tumors. Future Oncol. 2019;15(18):2151–2162. DOI:10.2217/fon-2018-0915
   PubMed Web of Science ®Google Scholar
• Linehan WM, Ricketts CJ. The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–552.
   PubMed Web of Science ®Google Scholar
• Bui TO, Dao VT, Nguyen VT, et al. Genomics of clear-cell renal cell carcinoma: a systematic review and meta-analysis. Eur Urol. 2022;81(4):349–361. DOI:10.1016/j.eururo.2021.12.010
   PubMed Web of Science ®Google Scholar
• Wang T, Lu R, Kapur P, et al. An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors. Cancer Discov. 2018;8(9):1142–1155. DOI:10.1158/2159-8290.CD-17-1246
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Ostrovnaya I, Reva B, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013;19(12):3259–3267. DOI:10.1158/1078-0432.CCR-12-3886
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng X, Xiong J, et al. 79P SETD2 a potential tissue-agnostic predictive biomarker for ICIs in solid tumors. Ann Oncol. 2021;32:S390.
   Web of Science ®Google Scholar
• Chen YW, Rini BI. Approaches to first-line therapy for metastatic clear cell renal cell carcinoma. Curr Oncol Rep. 2022;24(6):695–702.
   PubMed Web of Science ®Google Scholar
• Simonaggio A, Epaillard N, Pobel C, et al. Tumor microenvironment features as predictive biomarkers of response to immune checkpoint inhibitors (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). Cancers (Basel). 2021;13(2):231. DOI:10.3390/cancers13020231
   PubMed Web of Science ®Google Scholar
• Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61(13):5132–5136.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang E, Long J, et al. Immune infiltration in renal cell carcinoma. Cancer Sci. 2019;110(5):1564–1572. DOI:10.1111/cas.13996
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. DOI:10.1038/s41591-018-0014-x
   PubMed Web of Science ®Google Scholar
• Koh MY, Sayegh N, Agarwal N. Seeing the forest for the trees-single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer. Cancer Cell. 2021;39(5):594–596.
   PubMed Web of Science ®Google Scholar
• Braun DA, Hou Y, Bakouny Z, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–918. 10.1038/s41591-020-0839-y. .
   PubMed Web of Science ®Google Scholar
• Au L, Hatipoglu E, Robert de Massy M, et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell. 2021;39(11):1497–1518.e11. DOI:10.1016/j.ccell.2021.10.001
   PubMed Web of Science ®Google Scholar
• Bakouny Z, Braun DA, Shukla SA, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021;12(1):808. 10.1038/s41467-021-21068-9. .
   PubMed Web of Science ®Google Scholar
• Wan X, Song M, Wang A, et al. Microbiome crosstalk in immunotherapy and antiangiogenesis therapy. Front Immunol. 2021;12:747914.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97. DOI:10.1126/science.aan3706
   PubMed Web of Science ®Google Scholar
• Salgia NJ, Bergerot PG, Maia MC, et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. Eur Urol. 2020;78(4):498–502. DOI:10.1016/j.eururo.2020.07.011
   PubMed Web of Science ®Google Scholar
• Dizman N, Meza L, Bergerot P, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022;28(4):704–712. DOI:10.1038/s41591-022-01694-6
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Massari F, Albiges L, et al. Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. Eur Urol. 2015;68(1):154–160. DOI:10.1016/j.eururo.2014.10.034
   PubMed Web of Science ®Google Scholar
• Santoni M, Buti S, Conti A, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 2015;10(4):517–522. DOI:10.1007/s11523-014-0356-3
   PubMed Web of Science ®Google Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–150.
   PubMed Web of Science ®Google Scholar
• Bilen MA, Rini BI, Voss MH, et al. Association of neutrophil-to-lymphocyte ratio with efficacy of first-line avelumab plus axitinib vs. sunitinib in patients with advanced renal cell carcinoma enrolled in the phase 3 JAVELIN renal 101 trial. Clin Cancer Res. 2022;28(4):738–747. DOI:10.1158/1078-0432.CCR-21-1688
   PubMed Web of Science ®Google Scholar
• Lalani AA, Xie W, Martini DJ, et al. Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018;6(1):5. DOI:10.1186/s40425-018-0315-0
   PubMed Web of Science ®Google Scholar
• Navani V, Heng DYC. Treatment selection in first-line metastatic renal cell carcinoma-the contemporary treatment paradigm in the age of combination therapy: a review. JAMA Oncol. 2022;8(2):292–299.
   PubMed Web of Science ®Google Scholar
• Massari F, Rizzo A, Mollica V, et al. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. Eur J Cancer. 2021;154:120–127.
   PubMed Web of Science ®Google Scholar
• Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of metastatic clear cell renal cell carcinoma: aSCO guideline. J Clin Oncol. 2022;40(25):2957–2995.
   PubMed Web of Science ®Google Scholar
• Verbiest A, Renders I, Caruso S, et al. Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors. Clin Genitourin Cancer. 2019;17(5):e981–994. DOI:10.1016/j.clgc.2019.05.009
   PubMed Web of Science ®Google Scholar
• Vano YA, Elaidi R, Bennamoun M, et al. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):612–624. DOI:10.1016/S1470-2045(22)00128-0
   PubMed Web of Science ®Google Scholar
• Fontes-Sousa M, Magalhães H, Oliveira A, et al. Reviewing treatment options for advanced renal cell carcinoma: is there still a place for tyrosine kinase inhibitor (TKI) monotherapy? Adv Ther. 2022;39(3):1107–1125. DOI:10.1007/s12325-021-02007-y
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Ciccarese C, Procopio G, et al. Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. Cancer Treat Rev. 2022;105:102379.
   PubMed Web of Science ®Google Scholar
• Powles T, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): analysis of progression after first subsequent therapy in KEYNOTE-426. J Clin Oncol. 2022;40(16_suppl):4513. DOI:10.1200/JCO.2022.40.16_suppl.4513
   Web of Science ®Google Scholar
• Voss MH, Powles T, McGregor BA, et al. Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study. J Clin Oncol. 2022;40(16_suppl):4514. DOI:10.1200/JCO.2022.40.16_suppl.4514
   Web of Science ®Google Scholar
• Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): expanded efficacy analyses from KEYNOTE-564. J Clin Oncol. 2022;40(16_suppl):4512. DOI:10.1200/JCO.2022.40.16_suppl.4512
   Web of Science ®Google Scholar